Article Hero

Pfizer is developing an at-home pill against COVID-19

1619622229.png
Miguel A. Rodriguez
Miguel A. Rodriguez
29 April 2021
The middle of the week came with news from one of the most popular pharma companies right now due to its COVID-19 vaccine – Pfizer

Pfizer, the company that developed the first authorized COVID- 19 vaccine in the US, announced that it began in March an early-stage clinical trial of a new medicine for the disease. The new drug is a protease inhibitor and works by inhibiting an enzyme that the virus needs to replicate in human cells. These types of inhibitors are already being used in treating HIV and hepatitis C.

According to Pfizer CEO Albert Bourla, if everything goes smoothly and the FDA approves the drug, it will hit the shelves by the end of the year.

From the health experts’ perspective, the ingestible drug could be a game-changer because infected people could use it outside hospitals.

Besides the news drug, Pfizer is testing its vaccine in 6-months to 11-year-old children, after the company received from the FDA the authorization to expand its vaccine usage to adolescents aged between 12 – 15.

The market seemed to react positively to the news. At the moment of writing, Pfizer stock price is trading 0.57% higher.

Sources: cnbc.com, finance.yahoo.com

This information/research prepared by Miguel A. Rodriguez does not take into account the specific investment objectives, financial situation, or particular needs of any particular person. The research analyst primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views and consequently any person acting on it does so entirely at their own risk.The research provided does not constitute the views of KW Investments Ltd nor is it an invitation to invest with KW Investments Ltd. The research analyst also certifies that no part of his/her compensation was, is, or will be, directly, or indirectly, related to specific recommendations or views expressed in this report.The research analyst in not employed by KW Investments Ltd. You are encouraged to seek advice from an independent financial adviser regarding the suitability of the investment, under a separate engagement, as you deem fit that conforms to your specific investment objectives, financial situation, or particular financial needs before making a commitment to invest. The laws of the Republic of Seychelles shall govern any claim relating to or arising from the contents of the information/ research provided. 

Share this article

How did you find this article?

Awful
Ok
Great
Awesome

Read More

Miguel A. Rodriguez
Miguel A. Rodriguez
Financial Writer

Miguel worked for major financial institutions such as Banco Santander, and Banco Central-Hispano. He is a published author of currency trading books.